SOURCE: BioMedReports


May 17, 2011 13:31 ET

Coverage Report: Positive Developments Expected to Continue at Neptune Technologies

LOS ANGELES, CA--(Marketwire - May 17, 2011) - BioMedReports subscribers first heard about Neptune Technologies & Bioressources (NASDAQ: NEPT) a few weeks ago, but the stock is gaining more traction with investors and fund managers as Versant Partners analyst, Doug Loe, in an exhaustive, 87-page initiating coverage report on Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT) has issued positive notes on the company, including revenue forecasts and management plans to meet forecasted demand by increasing current plant production by 300%.

Promising results from new cholesterol drugs have helped call attention to Neptune, which is aiming for cholesterol/hyperlipidemia's ultimate prize, but unlike most companies dealing with clinical studies and regulatory approvals, Neptune is a revenue generating company whose products are already marketed and distributed in over 20 countries worldwide.

The Versant Partners' report, subtitled: "Krill oil franchise poised to outperform in multiple consumer and medical markets" features a few key points of note to investors and more details about NEPT are now available at:

In addition, investors interested in accessing BioMedReports' new Complete Database of Clinical Trials and Upcoming FDA and World-Wide Regulatory Decisions can go to:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets.

Full disclosures and information about the stocks are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:

    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556